 GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 GLOBE NEWSWIRE -- Emergent BioSolutions Inc. NYSE:EBS and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing CDMO services agreement spanning Emergents integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providences COVID-19 messenger RNA mRNA vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief. 